Effect of Unani Formulation in the Psoriasis of palms and soles
Phase 2
- Conditions
- Health Condition 1: L408- Other psoriasis
- Registration Number
- CTRI/2022/04/041570
- Lead Sponsor
- Rajiv Gandhi University Of Health Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient with m-PPPASI (Modified Palmoplantar Psoriasis Area Severity Index ) score up to moderate or 10-30% area involved at baseline
Patients must be able and willing to provide written informed consent and comply with the requirements of this study protocol
Exclusion Criteria
Patient taking treatment of psoriasis including PUVA therapy, systemic steroids or systemic immunosuppressantâ??s for the last one month and above.
Patient with erythrodermic psoriasis, generalized or localized pustular psoriasis.
Pregnant and lactating mothers.
Patients with Systemic disease
Patients suffering from other concomitant skin diseases like Vitiligo, Eczema, and Lichen Simplex & Seborrheic Dermatitis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method